Odonate, Inc. is a pharmaceutical company, which engages in the development of therapeutics that improve and extend the lives of patients with cancer. The company is headquartered in San Diego, California and currently employs 137 full-time employees. The company went IPO on 2017-12-07. The firm is focused on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The firm is no longer in development of tesetax.
Follow-Up Questions
Odonate Inc 的 CEO 是誰？
Mr. Kevin Tang 是 Odonate Inc 的 Chairman of the Board，自 2013 加入公司。
ODTC 股票的價格表現如何？
ODTC 的當前價格為 $0，在上個交易日 decreased 了 0%。
Odonate Inc 的主要業務主題或行業是什麼？
Odonate Inc 屬於 Pharmaceuticals 行業，該板塊是 Health Care
